Reported about 2 months ago
Hims & Hers Health's stock dropped significantly after Eli Lilly announced the release of a lower-priced version of its weight-loss drug Zepbound. Lilly's new offering, which allows users to measure doses themselves and is sold directly to consumers, poses fresh competition for Hims & Hers, which has been selling its own copycat injectable drugs like Wegovy and Ozempic. Following the news, Hims & Hers shares fell by 7% but are still up nearly 70% year-to-date.
Source: YAHOO